Provided by Tiger Fintech (Singapore) Pte. Ltd.

CRISPR Therapeutics AG

52.94
-1.1600-2.14%
Volume:1.01M
Turnover:53.53M
Market Cap:4.81B
PE:-9.73
High:54.32
Open:54.02
Low:52.00
Close:54.10
52wk High:71.13
52wk Low:30.04
Shares:90.95M
Float Shares:90.53M
Volume Ratio:0.83
T/O Rate:1.12%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.4437
EPS(LYR):-4.3416
ROE:-25.34%
ROA:-13.05%
PB:2.81
PE(LYR):-12.19

Loading ...

Crispr Therapeutics Is Maintained at Buy by B of A Securities

Dow Jones
·
Jul 23

CRISPR Therapeutics Pick of the Week at Smart Insider Following Simeon George's Stock Purchase

MT Newswires Live
·
Jul 22

AI Biotech Stocks Shined. Recursion Soared 10%; Absci Up 7%; Crispr Up 6%; Beam And Ginkgo Up 3%

Tiger Newspress
·
Jul 21

CRISPR Therapeutics AG Director George Simeon Reports Acquisition of Common Shares

Reuters
·
Jul 18

Crispr Therapeutics Price Target Maintained With a $81.00/Share by Needham

Dow Jones
·
Jul 08

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jul 08

Crispr Therapeutics Price Target Maintained With a $65.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 27

CRISPR Therapeutics Advances Phase 1 Trials for Cardiovascular Disease Programs

MT Newswires Live
·
Jun 26

Crispr Therapeutics Reports Positive Additional Phase 1 Data For Ctx310™ Targeting Angptl3 And Provides Update On In Vivo Cardiovascular Pipeline

Reuters
·
Jun 26

CRISPR Therapeutics AG Held Annual General Meeting of Shareholders

Reuters
·
Jun 10

CRISPR Therapeutics AG Files Initial Beneficial Ownership Statement for Director Morrison Briggs

Reuters
·
Jun 07

New Hope for Strokes And Heart Attacks -- Barron's

Dow Jones
·
May 31

CRISPR Therapeutics AG's Chief Medical Officer Naimish Patel Reports Disposal of Common Shares

Reuters
·
May 31

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

Dow Jones
·
May 29

Strokes and Heart Attacks Kill. New Drugs Are Coming to Prevent Them. -- Barrons.com

Dow Jones
·
May 23

Crispr Therapeutics Price Target Maintained With a $86.00/Share by JMP Securities

Dow Jones
·
May 21

Mizuho Cuts Price Target on CRISPR Therapeutics to $85 From $99, Keeps Outperform Rating

MT Newswires Live
·
May 21

CRISPR, Sirius Collaborate on RNA Therapy Targeting Blood Clot Disorders

MT Newswires Live
·
May 20

Crispr Therapeutics And Sirius Therapeutics Announce Multi-Target Collaboration To Develop Novel Sirna Therapies

Reuters
·
May 20

Crispr Therapeutics to Partner With Sirius Therapeutics to Develop siRNA Therapies

Dow Jones
·
May 20